NCT02072057View on ClinicalTrials.gov

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 20, 2014

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Cancer Cachexia
Interventions
DRUG

Ruxolitinib

Trial Locations (2)

4600

Division of Hematology/Oncology, Kantonsspital Olten, Olten

5001

Division of Hematology/Oncolgy, University Clinic of Medicine, Kantonsspital Aarau AG, Aarau

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Clinical Trial Unit, University Hospital Basel, Switzerland

OTHER

collaborator

University Hospital, Basel, Switzerland

OTHER

collaborator

Novartis

INDUSTRY

lead

Kantonsspital Aarau

OTHER